
Please try another search
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ products, functional products, dialysis products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products. This business also operates dialysis and training centers. The company’s Pharmaceutical-Related business engages in the contract manufacturing of pharmaceutical products with containers for combination products, including injectable kit products consigned by other pharmaceutical companies. The business also provides injectable and oral drugs products. Its PharmaPackaging business offers pharmaceutical packaging containers and glass tubing, such as molded components for vials, syringes, rubber stoppers, and devices used to administer pharmaceuticals; and glass for thermos bottles, lighting and containers for combination products, as well glass for ampoules. It serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Settsu, Japan.
Name | Age | Since | Title |
---|---|---|---|
Kawazu Hidehiko | - | 2022 | Independent Outside Director |
Kiyotaka Yoshioka | 71 | 2006 | Senior MD, Domestic Business Division Manager & Director |
Yoshihiko Sano | 79 | 1993 | Chairman of Board & President |
Takayuki Nomiya | 81 | 2008 | Chairman of Audit & Supervisory Board |
Toshiaki Masuda | 68 | 2015 | MD, Head of Planning and Development and Director |
Tsuyoshi Yamazaki | 56 | 2015 | Senior MD, Head of International Business Division & Director |
Kimihito Minoura | 52 | 2009 | MD, Head of Regenerative Medicine and Business Promotion, Business Management & Director |
Kazuhiko Sano | 72 | 2010 | MD, GM of Facilities Division & Production Technology Center and Director |
Toyoshi Yoshida | 61 | 2010 | Director of Quality Assurance Division & Director |
Yoshiko Tanaka | 75 | 2014 | Independent Lead Outside Director |
Kenichi Nishida | 54 | 2012 | MD, Head of Pharmaceutical Business Division and Pharmaceutical Production & Director |
Kyoetsu Kobayashi | 69 | 2014 | MD, GM of the Stable Production & Crisis Management Division and Director |
Yasushi Oyama | 62 | 2015 | MD, Head of Vascular Business Division & Director |
Hideto Nakamura | 66 | 2009 | GM of General Affairs, HR Division & Governance and Director |
Takehito Yogo | 56 | 2006 | Senior MD, CSO & Director |
Shimamori Yoshiko | 77 | 2021 | Independent Outside Director |
Hattori Toshiaki | 70 | 2022 | Independent Outside Director |
Yoshimori Toshikazu | 73 | 2024 | Independent Outside Director |
Kushida Yuka | 61 | 2024 | Independent Outside Director |
Shigeru Yanagase | 77 | 2023 | Outside Statutory Auditor |
Yoshitaka Akikuni | 71 | 2023 | Outside Statutory Auditor |
Imaizumi Yasuhiko | 68 | 2024 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review